Everest Medicines ("Everest" kapa "Company"), k'hamphani ea biopharmaceutical e tsepamisitseng maikutlo ho nts'etsopele le ho rekisa lihlahisoa tse fetolang meriana tse sebetsanang le litlhoko tsa bohlokoa tsa bongaka tse sa fihlelleheng bakeng sa bakuli ba Asia, kajeno e phatlalalitse hore e rekile likarolo tse tloaelehileng tsa 1,095,000 tse lekanang le hoo e ka bang HK $ 50 milione. 'marakeng o bulehileng nakong ea ho tloha ka la 4 Mphalane 2021 ho isa la 29 Mphalane 2021, ka karolelano ea theko ea HK$45.63 ka kabelo. Lintlha tsa khoebo ea motho ka mong li fumaneha karolong ea bo-ramatsete webosaeteng ea Khampani.
Thekollo e entsoe tlas'a HK$100 milione ea lenaneo la ho reka hape ka karolo e phatlalalitsoeng ho tloha ka la 30 Phato, 2021. Ka theko ea hona joale ea kabelo, Khampani e lumela hore likabelo tsa eona li hoeba ka theolelo e kholo ho boleng ba tsona, 'me e ka tsoelapele ho reka hape dishere mmaraka o bulehileng. Khampani e ikemiseditse ka botlalo ho thea boleng ba beng ba diabo mme e na le kgodiseho e matla mabapi le tebello ya yona ya bokamoso. Ho tloha ka la 30 Phuptjane 2021, Khamphani e ne e na le chelete e RMB3,971.0 milione le chelete e lekanang le eona.
Khampani e tla etsa thekollo efe kapa efe ea kabelo ho latela memorandamo le lingoliloeng tsa mokhatlo oa Khampani, Melao e Laolang Lenane la Securities ho The Stock Exchange ea Hong Kong Limited, Melao ea ho Kopanya Litheko le Likopano le Litheko tsa Kabelo, Molao oa Likhamphani oa Lihlekehleke tsa Cayman le melao le melaoana eohle e sebetsang eo Khampani e tlas'a eona.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Khampani e tla etsa thekollo efe kapa efe ea kabelo ho latela memorandamo le lingoliloeng tsa mokhatlo oa Khampani, Melao e Laolang Lenane la Securities ho The Stock Exchange ea Hong Kong Limited, Melao ea ho Kopanya Litheko le Likopano le Litheko tsa Kabelo, Molao oa Likhamphani oa Lihlekehleke tsa Cayman le melao le melaoana eohle e sebetsang eo Khampani e tlas'a eona.
- Or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, today announced that it has repurchased 1,095,000 ordinary shares equivalent to approximately HK$50 million in the open market in the period from October 4, 2021 to October 29, 2021, at an average price of HK$45.
- At current share price, the Company believes its shares are trading at a substantial discount to their underlying value, and may continue to repurchase shares in open market.
